S. Gastoldi

发表

Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

G. Remuzzi, M. Noris, F. Casiraghi, 2005, Thrombosis and Haemostasis.

Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant

G. Remuzzi, A. Benigni, P. Iatropoulos, 2020, Frontiers in Medicine.

Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis

G. Remuzzi, M. Noris, M. Galbusera, 2017, The Journal of Immunology.

This information is current as Activation in Disease Models Proconvertase and Inhibits Complement that Blocks Formation of the C3bB A Novel Antibody against Human Factor B

M. Noris, O. Llorca, B. Morgan, 2014 .

Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis

G. Remuzzi, P. Ruggenenti, M. Noris, 2021, Frontiers in Immunology.

Microvascular Thrombosis Exuberant C3a Formation That Triggers Complement by Shiga Toxin Promotes Alternative Pathway Activation of

G. Remuzzi, M. Gobbi, M. Morigi, 2011 .

Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation

G. Remuzzi, M. Morigi, D. Macconi, 2005, Xenotransplantation.

In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS 13 in thrombotic thrombocytopenic purpura

G. Remuzzi, R. Coppo, M. Noris, 2018 .

Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

G. Remuzzi, E. Daina, P. Perseghin, 2009, Thrombosis and Haemostasis.

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.

G. Remuzzi, E. Daina, J. Grünfeld, 2005, Blood.

Brief report Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report thrombocytopenic

E. Daina, M. Noris, F. Fakhouri, 2005 .

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

G. Remuzzi, A. Benigni, A. Perna, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.

G. Remuzzi, S. Rodríguez de Córdoba, M. Noris, 2015, Journal of the American Society of Nephrology : JASN.

ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

G. Remuzzi, M. Noris, F. Peyvandi, 2015, Clinical journal of the American Society of Nephrology : CJASN.

In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura

G. Remuzzi, R. Coppo, M. Noris, 2006, Thrombosis and Haemostasis.

Complement activation and effect of eculizumab in scleroderma renal crisis

M. Jadoul, Y. Pirson, P. Stordeur, 2016, Medicine.

ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes

G. Remuzzi, A. Benigni, G. Taraboletti, 2018, Diabetes.

SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation

G. Remuzzi, A. Benigni, P. Ruggenenti, 2022, Frontiers in Immunology.

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19

G. Remuzzi, A. Benigni, P. Ruggenenti, 2021, Blood advances.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Francesco Tedesco, Giuseppe Remuzzi, Piero Ruggenenti, 2014, Blood.

Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis

G. Remuzzi, M. Gobbi, M. Morigi, 2011, The Journal of Immunology.

In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies.

G. Remuzzi, A. Benigni, M. Morigi, 2005, The American journal of pathology.

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab

L. Weber, C. Bergmann, B. Hoppe, 2015, Pediatric Nephrology.

Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.

G. Remuzzi, S. Rodríguez de Córdoba, E. Goicoechea de Jorge, 2017, Journal of the American Society of Nephrology : JASN.

ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy

G. Remuzzi, P. Ruggenenti, M. Noris, 2013, Diabetes.

Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress.

G. Remuzzi, A. Remuzzi, B. Imberti, 2001, Blood.

Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study

G. Remuzzi, L. Lorini, A. Benigni, 2021, PloS one.

SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation

G. Remuzzi, A. Benigni, P. Ruggenenti, 2021, SSRN Electronic Journal.

A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models

S. Rodríguez de Córdoba, M. Noris, O. Llorca, 2014, The Journal of Immunology.

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

G. Remuzzi, P. Ruggenenti, V. Leone, 2022, Frontiers in Pharmacology.

An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome

G. Remuzzi, A. Benigni, M. Noris, 2023, Frontiers in Immunology.

Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

G. Remuzzi, M. Noris, F. Casiraghi, 2005, Thrombosis and Haemostasis.

Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity

S. Aiello, S. Gastoldi, Paulina Dabrowska-Schlepp, 2024, Frontiers in immunology.